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Abstract
Background: Chronic hepatitis C virus infection is prevalent and often causes hepatic fibrosis, which can
progress to cirrhosis and cause liver cancer or liver failure. Study of fibrosis progression often relies on imputing
the time of infection, often as the reported age of first injection drug use. We sought to examine the accuracy of
such imputation and implications for modeling factors that influence progression rates.
Methods: We analyzed cross-sectional data on hepatitis C antibody status and reported risk factor histories
from two large studies, the Women's Interagency HIV Study and the Urban Health Study, using modern survival
analysis methods for current status data to model past infection risk year by year. We compared fitted
distributions of past infection risk to reported age of first injection drug use.
Results: Although injection drug use appeared to be a very strong risk factor, models for both studies showed
that many subjects had considerable probability of having been infected substantially before or after their reported
age of first injection drug use. Persons reporting younger age of first injection drug use were more likely to have
been infected after, and persons reporting older age of first injection drug use were more likely to have been
infected before.
Conclusion: In cross-sectional studies of fibrosis progression where date of HCV infection is estimated from
risk factor histories, modern methods such as multiple imputation should be used to account for the substantial
uncertainty about when infection occurred. The models presented here can provide the inputs needed by such
methods. Using reported age of first injection drug use as the time of infection in studies of fibrosis progression
is likely to produce a spuriously strong association of younger age of infection with slower rate of progression.
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Background
Chronic hepatitis C virus (HCV) infection is prevalent
both in the United States, with perhaps 3 million persons
infected [1], and worldwide [2]. It often causes progressive
hepatic fibrosis. This can eventually become cirrhosis,
causing hepatocellular carcinoma, liver failure, a need for
liver transplant, or death. Fibrosis measured by liver
biopsy is believed to provide the most accurate measure-
ment of the extent of liver damage [3]. Considerable effort
has been devoted to estimating risk factors for infection
[4-13], as well as rates of progression through fibrosis
stages to cirrhosis [14-21]. Studies of HCV progression
often utilize liver biopsies from persons who may have
been originally infected many years or decades earlier. The
exact time of infection is often unknown, so the subjects'
self-reported risk factor histories are used to impute a pre-
sumed time of infection. A common practice is to assume
that infection occurred at the time of first reported injec-
tion drug use (IDU) [14,19,22]. Studies of infection risk
factors support this practice to a limited extent by showing
that IDU is a strong risk factor [4,5,7,8,12]. Here, we
assess in more detail how accurate such imputation is
likely to be. We utilize cross-sectional HCV antibody sta-
tus data and self-reported risk-factor histories, similar to
the situation in progression studies where time of infec-
tion must be imputed. In contrast to the usual statistical
modeling in risk factor studies, which utilizes logistic
regression with potential risk factors modeled as fixed
covariates, we use survival analysis methods with time-
varying covariates. This is possible even though every
observation is either left-censored (infection occurred at
some unknown time in the past) or right censored (infec-
tion has not yet occurred). An advantage of this approach
is that it permits reconstruction of past risk year by year,
which facilitates assessment of possible biases or inaccu-
racies in the usual imputation strategy, along with the
implications for modeling of factors that influence fibro-
sis progression.
Methods
Study population
We analyzed data from two large studies that performed
HCV antibody (anti-HCV) testing and collected subject
reports concerning history of IDU. The Women's Intera-
gency HIV Study (WIHS), as previously described [23,24],
includes women with or at risk for HIV infection. This
study performed anti-HCV testing of initial participants,
mainly in 1994–1995, and additional participants who
were recruited in 2001–2002. The results used here were
obtained using a second generation HCV enzyme immu-
noassay for most subjects, with a few of the newer recruits
having data from a third generation test. The Urban
Health Study (UHS) was composed of street-recruited
injection drug users in the San Francisco Bay Area and has
also been described previously [25-27]. Participants
included here were recruited from 1987 to 2002, and sec-
ond generation anti-HCV testing was performed for spec-
imens from 1987 and from 1998–2002, as well as the
initial specimens regardless of year for all subjects who
reported IDU duration of < 10 years. For our analyses of
both studies, we included only the first anti-HCV result
from each participant and did not include any subsequent
longitudinal follow up. This was to reduce cohort partici-
pation bias [12,28,29], and to approximate the common
situation in cross-sectional studies of patients presenting
with chronic HCV infection with no prior HCV test
results. We also required that subjects have valid data on:
sex; race; HIV antibody; ages of first and last IDU, if any;
age and calendar year of HCV test; and for those with a
history of IDU, whether they typically injected every day.
For UHS, we assumed that subject's reported current injec-
tion frequency was typical of their entire IDU history
because no other information was available about fre-
quency of injection. WIHS subjects were asked to report a
single typical frequency for all the time when they were
injecting. Histories of needle sharing practices were not
collected in either study. Because needle sharing behavior
may have changed substantially over time due to the
emergence of HIV and subsequent efforts to prevent its
spread, current sharing would not be an adequate surro-
gate for past practices; we therefore did not assess this risk
factor. Data on blood transfusion history was not required
for inclusion in our analyses because it was only partially
ascertained in WIHS (transfusions in the years
1975–1985, only among those recruited in 1993–94) and
was not collected in UHS.
Statistical methods
The available data indicate only whether or not each sub-
ject was infected with HCV at some point in the past, a
form of information known in the statistical literature as
current status data [30-33]. We used maximum full likeli-
hood to fit parameters of discrete-time survival models,
using year of age as the time scale. Beginning with age 1
(where risk was very small in all models), the log-odds of
HCV infection given no previous infection was modeled
as a linear function of covariates that pertained to that
year, including age, calendar year, and whether the subject
reported using injection drugs during that year. The fitted
log-odds were then converted to hazards and combined
across years to obtain a predicted probability of being
HCV seropositive at the age tested. The NLMIXED proce-
dure in the SAS statistical package (version 9.1, SAS Insti-
tute, Cary, NC) was used to obtain the parameter
estimates that maximized the resulting likelihood, along
with their confidence intervals (CI) and p-values. This
approach is similar to Cox's discrete-time partial likeli-
hood model [34], except that the role of time (in this case
age) is modeled instead of being conditioned out in a par-
tial likelihood. It can also be considered a form of pooledBMC Infectious Diseases 2007, 7:145 http://www.biomedcentral.com/1471-2334/7/145
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logistic regression [35] with a parsimonious model for the
effect of time instead of an unstructured model. Estimated
effects of covariates are presented as odds ratios (OR's).
We provide in Additional File 1 the SAS NLMIXED code
for fitting one of the models presented below.
Because HCV risk associated with IDU may vary depend-
ing on duration of IDU [7,12,36], we defined separate
time-varying indicator variables for the reported first year
of use, the second or third year, and the fourth or greater
year. In defining the hazard at each age, we assumed that
IDU began in the middle of the reported age of first use;
instead assuming that IDU began at the beginning pro-
duced qualitatively similar results, but may be a less accu-
rate assumption. We also examined further breakdown of
duration into fourth to tenth year versus 11th or greater
year. For the time-varying numeric covariates age and cal-
endar year, we examined linear models, quadratic models,
and more flexible models based on parametric cubic
splines defined by the ns() function in S-Plus (Insightful
Corporation, Seattle, WA), choosing a model by likeli-
hood ratio testing of nested alternatives. We examined
plausible interactions one at a time by adding the product
of the two predictors to the model with main effects only.
To limit the complexity of interactions with reported IDU,
we assumed common interactions for the reported first,
second-third, and fourth or greater years of IDU.
We used the fitted multivariate models to calculate esti-
mated distributions of age at HCV infection given each
subject's age at first positive HCV antibody test and
reported risk factor profile. For each subject and each pos-
sible age of infection, this produced a probability that
infection occurred at that age. To compare these to the
usual imputation of age at HCV infection as the reported
age of first IDU, we calculated the mean age at infection
from the estimated probabilities and calculated the usual
imputation's bias as the age of first IDU minus this mean.
We also calculated the probability that infection occurred
at the reported age of first IDU or the next year, consider-
ing this to be the probability that the usual imputation
would be reasonably accurate.
Results
Descriptive summaries
The characteristics of 2248 WIHS participants and 4623
UHS participants analyzed in this study are summarized
in Table 1. Both studies contain sufficient numbers of
HCV seropositive and seronegative subjects to permit
analysis of risk factors, but there are substantial differ-
ences between the studies due to different target popula-
tions and inclusion criteria. Although WIHS enrolled
3766 women, IDU history was only assessed in enough
detail for the present study 8 years after initial enrollment.
At that time, 2318 women provided information on ages
of IDU, if any, and 70 of these (3.0%) were excluded for
lack of valid data on other key variables. Of 4734 poten-
tial UHS participants, 111 (2.3%) were excluded due to
lack of valid data on key variables.
Table 2 shows detailed data on HCV prevalence by
reported total duration of IDU in the two studies. This
shows increasing prevalence of HCV seropositivity even at
long durations, suggesting continuing risk among those
who avoid infection early on. This also suggests that not
everyone who is infected with HCV due to IDU is infected
in the first year, as is commonly assumed.
Models for HCV infection risk
Multivariate models of HCV risk for WIHS and UHS are
shown in Table 3 and Figure 1. The estimated background
risk for these models was 0.0051 (95% CI 0.0028 to
0.0091) for WIHS and 0.034 (95% CI 0.021 to 0.055) for
UHS. This is the fitted probability of being infected with
HCV over the course of a year at age 30 in 1975 for a pre-
viously HCV-uninfected, (reportedly) non-injecting, HIV-
uninfected Caucasian female in the San Francisco area.
Fitted probabilities for other situations and types of sub-
jects are obtained by applying the OR's shown in Table 3
and Figure 1 to these background rates. Both cohorts pro-
duced some qualitatively similar results, including
decreased risk at younger ages and more recent calendar
years, as well as highest risk in the reported first year of
IDU. Despite these similarities, there were too many
quantitatively substantial differences to permit a simple
model of both studies pooled. These include the back-
ground risk when not injecting, the shape of the drop in
risk as reported duration of IDU increases, the role of daily
IDU, the strength of the influence of age, and racial/ethnic
associations. The model shown in Figure 1b for UHS is a
parametric spline with knots at 1980, 1990, and 1995,
because this provided an improved fit to the data com-
pared to a quadratic model (p = 0.0028), even though its
overall shape is roughly quadratic. The other curves in Fig-
ure 1 are all quadratic, because these improved substan-
tially over linear models (WIHS p = 0.0003 for age and p
= 0.0054 for calendar year; UHS p = 0.018 for age), but
parametric splines with up to 4 parameters did not appear
to substantially improve the fits further (all p > 0.22).
We examined a number of possible additions or refine-
ments to the models shown. Including blood transfusion
history in the WIHS model would result in losing 995 sub-
jects with missing data for this variable, and it did not
appear to be an important predictor (OR 1.10, 95% CI
0.74 to 1.65, p = 0.64). Allowing for differing effects of age
when reportedly injecting versus not injecting did not pro-
duce substantially better fits to the data (WIHS p = 0.38,
UHS p = 0.21 by likelihood ratio tests). Other interaction
terms examined included calendar year by reported IDUBMC Infectious Diseases 2007, 7:145 http://www.biomedcentral.com/1471-2334/7/145
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Table 1: Characteristics of WIHS and UHS subjects analyzed for this study.
N in category (% of total)
Characteristic WIHS (N = 2248) UHS (N = 4623)
HCV seronegative 1666 (74.1%) 576 (12.5%)
HCV seropositive 582 (25.9%) 4047 (87.5%)
Year of HCV test
1987–1992 0 (0.0%) 572 (12.4%)
1993 29 (1.3%) 48 (1.0%)
1994 844 (37.5%) 47 (1.0%)
1995 306 (13.6%) 57 (1.2%)
1996 2 (0.1%) 62 (1.3%)
1997 4 (0.2%) 37 (0.8%)
1998 76 (3.4%) 862 (18.6%)
1999 15 (0.7%) 995 (21.5%)
2000 24 (1.1%) 904 (19.6%)
2001 635 (28.2%) 907 (19.6%)
2002 313 (13.9%) 132 (2.9%)
Age at HCV test
< 20 58 (2.6%) 67 (1.4%)
20–29 593 (26.4%) 488 (10.6%)
30–39 1048 (46.6%) 1200 (26.0%)
40–49 486 (21.6%) 1925 (41.6%)
50–59 58 (2.6%) 810 (17.5%)
60+ 5 (0.2%) 133 (2.9%)
Female 2248 (100%) 1409 (30.5%)
Male 0 (0%) 3214 (69.5%)
Race/Ethnicity
Caucasian 275 (12.2%) 1684 (36.4%)
African American 1277 (56.8%) 2232 (48.3%)
Hispanic 615 (27.4%) 401 (8.7%)
Other 81 (3.6%) 306 (6.6%)
Area
San Francisco 340 (15.1%) 4623 (100%)
Bronx 459 (20.4%) 0 (0%)
Brooklyn 429 (19.1%) 0 (0%)
Washington, DC 320 (14.2%) 0 (0%)
Los Angeles 397 (17.7%) 0 (0%)
Chicago 303 (13.5%) 0 (0%)
HIV-infected 1627 (72.4%) 787 (17.0%)
Ever IDU 522 (23.2%) 4623 (100%)
Age of First IDU
Before 12 4 (0.8%) 123 (2.7%)
12–15 69 (13.2%) 972 (21.0%)
16–19 163 (31.2%) 1520 (32.9%)
20–29 227 (43.5%) 1416 (30.6%)
30–39 56 (10.7%) 464 (10.0%)
40+ 3 (0.6%) 128 (2.8%)
Year of First IDU
Before1960 2 (0.4%) 198 (4.3%)
1960–1969 78 (14.9%) 1174 (25.4%)
1970–1979 206 (39.5%) 1473 (31.9%)
1980–1989 173 (33.1%) 1015 (22.0%)
1990–1995 43 (8.2%) 459 (9.9%)
After1995 20 (3.8%) 304 (6.6%)
Daily IDU 341 (65.3%) 2992 (64.7%)BMC Infectious Diseases 2007, 7:145 http://www.biomedcentral.com/1471-2334/7/145
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(WIHS p = 0.64, UHS p = 0.39), year by age (WIHS p =
0.37, UHS p = 0.065), race by IDU (WIHS p = 0.13, UHS
p = 0.29), and sex by IDU (UHS p = 0.54). We also exam-
ined models with IDU effects differing for the 4th to 10th
years of reported IDU versus beyond the 10th (WIHS p =
0.33, UHS p = 0.17). We note that the confidence intervals
were not narrow enough to rule out potentially important
interactions, but in the absence of strong evidence for
such interactions we focus on the simpler models without
them. One interaction that did reach statistical signifi-
cance was reported IDU by location in the WIHS study (p
= 0.029 overall). This was mainly due to reported IDU
being estimated to be less risky in the Bronx (IDU OR's
estimated to be smaller by a factor of 0.38, 95% CI 0.16 to
0.91) and Brooklyn (OR's smaller by a factor of 0.42, 95%
CI 0.16 to 1.14). The OR's for the main effects of these
locations were higher when the interaction was included
than those shown in Table 3 (Bronx OR 2.3, Brooklyn OR
1.41). These differences make the Bronx and Brooklyn
more similar to the UHS model, with lower OR's for
reported IDU and a higher background risk. Nevertheless,
the OR for the reported first year of IDU in the Bronx
remains nearly 3-fold larger than that in the UHS model.
Because we already show details for the UHS model, we
do not provide any further details on this WIHS model
with interaction terms.
Reconstruction of yearly past infection probabilities for 
those infected
Table 4 summarizes the models' fitted past risks for a
number of situations and compares these to the reported
age of first IDU, the usual imputed age at HCV infection.
Scenarios 1–4 illustrate the impact of different ages at
time of HCV antibody test and first IDU, while the
remaining scenarios are based on extreme situations
observed in the actual data sets. The alternatives at the
bottom of the table illustrate the relatively minor impacts
of different locations in WIHS and of male sex in UHS.
Among all HCV seropositive subjects with IDU history,
the median fitted probability that HCV infection occurred
the year of first IDU or the next year was 0.77 for WIHS
(range 0.23 to 0.93) and 0.56 for UHS (range 0.01 to
0.82). The lower values for UHS reflect its higher esti-
mated background risk when reportedly not injecting and
Table 3: Multivariate models of HCV infection risk.
Women's Interagency HIV Study San Francisco Urban Health Study
Variable Odds Ratio 95% CI p Odds Ratio 95% CI p
Injection drug use (versus not injecting)
1st year of use 310 163 to 588 < 0.0001 61 21 to 177 < 0.0001
2nd & 3rd year 163 65 to 404 < 0.0001 9.8 1.94 to 50 0.0058
4th or later year 7.2 2.1 to 24.2 0.0015 5.2 3.2 to 8.4 < 0.0001
Daily IDU (versus less frequent IDU) 1.14 0.73 to 1.77 0.57 1.59 1.40 to 1.81 < 0.0001
Male sex (All Women) 0.76 0.67 to 0.85 < 0.0001
Age See Figure 1a < 0.0001 See Figure 1a 0.0001
Calendar Year See Figure 1b < 0.0001 See Figure 1b < 0.0001
Race/ethnicity (versus Caucasian)
African American 1.50 1.05 to2.1 0.027 0.86 0.76 to 0.97 0.014
Hispanic 1.64 1.09 to 2.5 0.018 1.44 1.15 to 1.81 0.0018
Other 1.38 0.66 to 2.9 0.40 0.94 0.76 to 1.16 0.57
Area (versus San Francisco)
Bronx 1.41 0.96 to 2.1 0.080 (All San Francisco area)
Brooklyn 0.90 0.58 To 1.39 0.63
Washington DC 1.10 0.70 To 1.73 0.68
Los Angeles 0.80 0.51 to 1.26 0.33
Chicago 1.70 1.11 to 2.6 0.015
HIV infected 1.56 1.16 to 2.1 0.0030 1.27 1.09 to 1.47 0.0017
Table 2: HCV Antibody status by duration of injection drug use 
(IDU) at time of testing.
HCV seropositive/Total (%)
Duration of IDU WIHS UHS
None 148/1726 (8.6%)
1 year 5/9 (55.6%) 59/151 (39.1%)
2 years 5/8 (62.5%) 56/104 (53.8%)
3 years 6/11 (54.5%) 59/104 (56.7%)
4–5 years 13/20 (65.0%) 138/209 (66.0%)
6–7 years 15/21 (71.4%) 148/202 (73.3%)
8–10 years 33/43 (76.7%) 275/335 (82.1%)
11–15 years 84/102 (82.4%) 360/439 (82.0%)
16–20 years 91/109 (83.5%) 497/556 (89.4%)
21–30 years 167/184 (90.8%) 1345/1394 (96.5%)
> 30 years 15/15 (100%) 1110/1129 (98.3%)BMC Infectious Diseases 2007, 7:145 http://www.biomedcentral.com/1471-2334/7/145
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its smaller OR's for the effect of IDU (Table 3). When aver-
aged over all subjects, mean bias was less than 1 year in
both studies, because age of reported first IDU was some-
times too early and sometimes too late. There was, how-
ever, a strong correlation of bias with reported age of first
IDU; the Pearson correlation was 0.78 (95% CI 0.73 to
0.81) in WIHS and 0.83 (95% CI 0.82 to 0.84) in UHS.
Figure 2 illustrates this association, showing that those
reporting first IDU before age 15 have average predicted
ages of infection that are substantially after first IDU,
while those reporting first IDU after age 30 have average
predicted infection ages that can be many years before first
reported IDU.
Discussion
Using modern statistical methods and large data sets, we
were able to obtain models for HCV infection risk that can
be used to produce year-by-year estimates of past infec-
tion risk. Similar to many epidemiological studies, we
found high risk in the reported first year of IDU
[4,5,7,8,12] and decreasing risk in recent calendar years
[22,37-40]. For a patient or research subject newly discov-
ered to be HCV-infected, these models permit calculating
the estimated probability that infection occurred at each
year in the past based on IDU history and other character-
istics. For the subjects studied here, results of such calcu-
lations suggest that the common approach of imputing
the age of infection as the reported age of first IDU is unre-
liable.
Some implications for modeling of fibrosis progression
Although the average difference between reported age of
first IDU and the fitted mean infection times from the
models was small for both WIHS and UHS, this does not
imply that modeling of fibrosis progression will be accu-
rate if it assumes infection at reported age of first IDU.
Large errors in one direction cancelled large errors in the
other, and there was usually a considerable chance that
infection occurred before or after the first reported year of
IDU. Such uncertainty necessitates a multiple imputation
strategy [41] or other advanced statistical method to avoid
both biased estimates and inappropriately narrow confi-
dence intervals. Most importantly, the strong correlation
of errors with reported age at first IDU implies that the
usual imputation can lead to spurious associations of
fibrosis progression with age at first IDU. For example,
consider one patient matching scenario 1 in Table 4 who
shows Metavir [42] fibrosis stage 4 (cirrhosis) by liver
biopsy at age 40, and another patient matching scenario 3
who shows fibrosis stage 2 at age 40. If we calculate pro-
gression rate as observed stage divided by duration of
infection [14], we get very different comparisons depend-
ing on what we assume about age of infection. Using
reported age of first IDU, the patient reporting first IDU at
age 12 has a rate of 0.143 fibrosis points per year, while
the one reporting first IDU at age 35 has a rate of 0.400,
nearly three times as fast. But using the fitted means from
the UHS model completely eliminates this difference,
producing rates of 0.161 and 0.148.
Additional sources of similar possible bias
The above bias toward making earlier age of HCV infec-
tion look spuriously protective against rapid progression
is further compounded by other sources of bias. Many
clinic-based progression studies have utilized patients
whose HCV infection is discovered due to related symp-
toms. This may exaggerate progression rates compared to
the entire population of HCV-infected persons [18], but it
can also produce a spurious protective effect of earlier age
of infection. Consider 4 persons who all would develop
symptoms and have their HCV infection discovered once
they reach fibrosis stage 3. Two are fast progressors who
reach stage 3 in 15 years, one infected at age 15 and one at
Estimated effects of age and calendar year for the multivari- ate models of HCV infection risk Figure 1
Estimated effects of age and calendar year for the 
multivariate models of HCV infection risk. WIHS: solid 
lines; UHS: dashed lines. Vertical bars are pointwise 95% con-
fidence intervals. a) Estimated odds ratios for age. The refer-
ence age is 30, where the odds ratio is 1.0 by definition. b) 
Estimated odds ratios for calendar year. The reference year 
is 1975, where the odds ratio is 1.0 by definition.
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age 40. The other two are slow progressors who will reach
stage 3 in 45 years, again with one infected at age 15 and
one at age 40. Among these 4 persons, progression is not
associated with age at infection. Nevertheless, mortality
risk unrelated to HCV makes the slow progressor infected
at age 40 much less likely than the one infected at age 15
to ever be included in a clinic-based study, while the dif-
ference in unrelated mortality risk for the fast progressors
is considerably less. This differential selection pressure
implies that in clinic-based studies slow progressors will
be under-represented among those infected at older ages
compared to those infected at younger ages, producing an
apparent protective effect of younger age at infection.
An additional difficulty is distinguishing a fixed effect due
to age at infection from a time-varying effect that changes
as a patient ages. For example, progression may accelerate
with increasing age so that the rate of progression is 2-fold
faster at age 60 than it would be at age 30, given the same
duration of disease and other characteristics. Those
infected at younger ages would then have more of their
disease course occur at younger ages when progression is
slower, causing them to progress more slowly overall even
if age at infection itself has no direct effect and even
though they experience the same acceleration once they
reach older ages. This again could produce a misleading
protective effect of younger age at infection. Carefully dis-
tinguishing a fixed versus time-varying role for age in
fibrosis progression will likely require multi-state mode-
ling algorithms [20] that allow for time-varying covari-
ates, which are currently not available. An analysis of
similar issues concerning the role of age in variant Creut-
zfeldt-Jakob disease [43] required customized analysis to
reveal that previous analyses had reached apparently mis-
taken conclusions. Similar efforts may be worthwhile for
HCV.
Limitations
The current status data available in this cross-sectional
study are less informative than knowing exact times of
HCV infection from a longitudinal study, but the large
sample sizes allowed our methods to produce models
with many plausible features, reasonably narrow confi-
dence intervals, and many small p-values. Importantly,
this cross-sectional situation matches that of many pro-
gression studies where subjects are found to be chroni-
cally HCV infected without any direct information on
when they became infected [14-21]. Although potentially
counterintuitive, this type of data does permit estimation
of effects of calendar time before the year of the first HCV
antibody test and of the background risk without IDU
despite the lack of anyone with no IDU in the UHS study.
This is because the current status data provide informa-
tion about cumulative risk over all years before the meas-
urement of the outcome, and because we had
considerable variation in the ages, calendar years, and
Table 4: Summaries of fits from multivariate models described by Table 3 and Figure 1. Except as noted, area is San Francisco and sex 
is female.
WIHS Model UHS Model
Age of Infection Age of Infection Age of Infection
Scenario Year of 
Birth
First 
IDU
Last 
IDU
HCV Ab 
+ Test
Daily 
IDU
Race/Ethnicity Probability First 
IDU Accurate*
Fitted 
Mean
Bias† Probability First 
IDU Accurate*
Fitted 
Mean
Bias†
1 1960 12 40 40 No Caucasian 0.38 17.5 -5.5 0.52 15.2 -3.2
2 1940 12 60 60 No Caucasian 0.07 29.2 -17.2 0.18 22.4 -10.4
3 1960 35 40 40 No Caucasian 0.66 34.7 0.3 0.39 26.5 8.5
4 1940 35 60 60 No Caucasian 0.74 35.5 -0.5 0.47 32.3 2.7
5 1943 14 50 52 Yes Hispanic 0.30 21.9 -7.9 0.58 16.2 -2.2
6 1943 14 50 52 No Caucasian 0.19 25.4 -11.4 0.33 20.5 -6.5
7 1972 21 22 22 Yes Hispanic 0.96 21.2 -0.2 0.71 18.5 2.5
8 1977 16 18 18 Yes Caucasian 0.83 16.7 -0.7 0.81 15.5 0.5
9 1942 56 57 57 Yes African American 0.09 34.3 21.7 0.07 31.4 24.6
10 1917 15 70 70 Yes African American 0.01 41.2 -26.2 0.01 39.4 -24.4
2 – LA‡ 1940 12 60 60 No Caucasian 0.07 29.6 -17.6
9 – LA‡ 1942 56 57 57 Yes African American 0.09 34.4 21.6
2 – Ch§ 1940 12 60 60 No Caucasian 0.09 28.0 -16.0
9 – Ch§ 1942 56 57 57 Yes African American 0.08 34.0 22.0
2 – Male 1940 12 60 60 No Caucasian 0.14 24.1 -12.1
9 – Male 1942 56 57 57 Yes African American 0.08 32.0 24.0
* Fitted probability that infection occurred in either the year of first IDU or the year after.
† Age at first IDU minus the predicted mean age of infection from the model for that scenario.
‡ Los Angeles area § Chicago areaBMC Infectious Diseases 2007, 7:145 http://www.biomedcentral.com/1471-2334/7/145
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reported durations of IDU at the time of HCV antibody
testing. For example, information on background risk
when reportedly not injecting can be obtained by compar-
ing the HCV prevalence of persons with 1 year of IDU
tested at age 20 versus persons with 1 year of IDU tested
at age 40, because they have different amounts of non-
IDU time. This comparison also provides information on
the risk of the first year of IDU, because this is the risk the
two groups have in common after the difference in back-
ground risk is accounted for. Our analyses synthesize
many such comparisons to produce the estimates.
The self-reported risk factor histories we have used may be
inaccurate, due to inaccurate recall or social desirability
bias. Indeed, some (or most) of the apparent background
risk of infection in the absence of IDU could be due to
inaccurate recall or report of ages of IDU. Our results
therefore do not necessarily imply substantial risk from
sources other than IDU and therefore should not be inter-
preted as contradicting the established belief that IDU is
the overwhelmingly predominant source of chronic HCV
infections. Some of the 8.6% prevalence of HCV seropos-
itivity among WIHS subjects reporting no IDU could
reflect infections caused by forgotten or unreported IDU.
More importantly, the estimated risk in the absence of
IDU is very high in UHS, much higher than in WIHS,
reaching incidence of 3.4% per year for the riskiest calen-
dar year and riskiest age. This is reflected in Figure 2b,
where 31% of the predicted mean infection ages are
before the reported age of first IDU (points above the hor-
izontal line). Utilizing the entire fitted distributions
instead of just the predicted means, we obtained an esti-
mate of 17% of UHS subjects being infected before their
reported age of first IDU. Although there is likely to be
some risk in the absence of IDU, particularly in this high-
risk population, and one study found a similarly high
prevalence of HCV infection among users of non-injec-
tion drugs [44], we believe that much of the risk predicted
by the model may reflect inaccurate reporting of ages of
first IDU. Thus, our models' fitted background risks may
reflect risk in the absence of reported IDU, but they may be
inaccurate estimates of risk when there really is no IDU.
Fortunately, this fits with our primary purpose of studying
imputation of age of infection based on reported risk factor
history, which is what must often be done in studies of
fibrosis progression. For this purpose, it is irrelevant
whether risk of infection before reported age of first IDU
results from non-IDU sources of risk or from unreported
IDU. In either case, imputation may be inaccurate.
One aspect that does not match the situation in progres-
sion studies is the use of HCV serology as the outcome.
The reconstructed yearly risks summarized in Table 4 and
Figure 2 are conditional on HCV seropositivity instead of
being conditional on confirmed chronic HCV infection
(by HCV RNA), which will be the case in progression stud-
ies. The proportion of HCV seropositive persons who clear
the virus and become HCV RNA- is thought to be about
20% overall [45] and 15% among HIV-infected persons
[46]. A model of clearance probabilities utilizing age and
other characteristics could in principle be synthesized
with the models presented here to produce more relevant
reconstructed past infection probabilities that are condi-
tional on chronic HCV infection. In addition, some
chronically HCV infected persons may test HCV seroneg-
ative, particularly by the second generation assay mainly
used here. In one study of HIV-infected persons, 37 of 617
(6%) with HCV infection were observed to be HCV nega-
tive by second generation antibody assay [46]. We note
that some of these 37 cases may have been recently
infected and not yet produced antibodies, which would
Estimated biases resulting from imputing age at HCV infec- tion as the age of first IDU Figure 2
Estimated biases resulting from imputing age at 
HCV infection as the age of first IDU. Bias is defined 
here as the reported age of first IDU minus the fitted mean 
from the multivariate models described by Figure 1 and Table 
3. Circles below the horizontal line represent subjects who 
are likely to have been infected after their first IDU, while 
those above represent subjects likely to have been infected 
before their first IDU. We have added random numbers 
ranging from -0.4 to +0.4 to the integer ages in order to 
increase the visibility of distinct points. Included are HCV 
seropositive subjects with some history of IDU. a) WIHS 
data, n = 434; b) UHS data, n = 4047.
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not be typical of subjects in HCV progression studies.
Exposure to HCV that results in neither chronic infection
nor HCV seropositivity [47] does not affect the validity of
our results, because such events do not initiate progres-
sion of HCV-related liver damage and are correctly treated
as such in our analyses.
The necessary exclusion of persons who died before the
conduct of the study could result in biased estimates of
risk factors, and any such "survivor bias" may be worse in
the WIHS, where participants also had to survive to the
visit where IDU history was assessed. For example, if those
who die of overdose in the first year of IDU are much
more likely to have been HCV infected, then their exclu-
sion will result in an underestimate of the HCV risk during
the first year of IDU. We note, however, that cross-sec-
tional progression studies will also necessarily have
excluded persons who die before being tested for HCV.
Thus, our estimates remain relevant for our primary pur-
pose of assessing estimation of past infection times in
such studies.
Being HIV positive was included as a fixed risk factor in
multivariate models, because the timing of HIV infection
was not known for most HIV-infected subjects. This
assumption could make sense if HCV risk associated with
being HIV infected was mainly due to other risk factors
(such as membership in a risky social network) that are
not directly available for modeling but are associated with
HIV infection and were present even before HIV infection.
If the mechanism of HIV-associated risk is directly causal,
such as greater susceptibility to HCV when HIV infection
is already present, then this effect would not be present
before HIV infection occurred. In this case, our estimates
based on HIV as a fixed risk factor would be attenuated
compared to what would be estimated if the timing of
past HIV infection were known. Although IDU might be
expected to usually result in HCV infection before it
causes HIV infection, sexual HIV risk is important among
drug users [26], so HIV could precede HCV infection often
enough that the possibility of attenuation cannot be ruled
out.
Despite many qualitative similarities, the differences
between the WIHS and UHS models leave considerable
uncertainty about how to impute ages of infection for a
progression study. Because inclusion of WIHS partici-
pants required retention in the study until IDU history
was assessed, these may be less similar than UHS partici-
pants to cross-sectional progression study participants,
while perhaps being more similar to subjects who are
retained in longitudinal follow-up. A desirable design
would be a large cross-sectional study ascertaining chronic
HCV infection and risk factor histories, followed by fibro-
sis progression measurement in those found to be HCV-
infected. Infection models fit to the cross-sectional data
would then be directly applicable to the progression mod-
eling. (The most desirable design, prospectively ascertain-
ing incident infections and subsequently monitoring
progression, would likely be prohibitively difficult.) In
the absence of such directly relevant models of past risk, a
sensible strategy may be to perform sensitivity analyses
using both models presented here, along with the usual
imputation based on first year of IDU. In addition, within
each model different specific choices about whether to
include and how to model each predictor, as well as
whether to include some interaction terms, could in some
cases be reasonable. This adds additional uncertainty
about specific imputations, but additional uncertainty
only adds further support for our conclusion that the
common single-imputation strategy is dangerous.
Conclusion
We have shown that, in cross-sectional HCV progression
studies that rely on risk factor histories to impute time of
HCV infection, there is usually considerable uncertainty
about when HCV infection may have occurred, even for
patients or research subjects reporting a history of IDU.
This should be accounted for in such progression studies,
preferably using modern methods such as multiple impu-
tation [41]. To facilitate use of such methods, we provide,
in Additional File 2, code that produces individuals' past
infection probabilities year by year. Use of single imputa-
tion can not only produce confidence intervals that are
too narrow and p-values that are too small, but also
severely biased estimates of covariate effects. In particular,
the usual strategy of imputing age of HCV infection as the
age of first reported IDU is likely to produce bias toward
finding slower progression associated with younger age of
infection. This bias could be further exacerbated by differ-
ential selection effects according to age of infection, and
by time-varying effects of current age being mis-modeled
as fixed effects of age at infection. Some or all of the pro-
tective effect of younger age at infection [14,19] found in
cross-sectional studies of fibrosis progression could there-
fore be spurious.
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